Evidence map›Paper›PMID 37165014›Full record

ReviewCellular & molecular immunology2023

Current perspectives on mesenchymal stromal cell therapy for graft versus host disease.

Nadir Kadri, Sylvie Amu, Ellen Iacobaeus, Erik Boberg, Katarina Le Blanc

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular & molecular immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
27.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 95 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Baseline CD4Journal of blood medicine · 2025
    Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Review
  10. [Research advances in mesenchymal stem cell therapy for graft-versus-host disease].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nadir KadriDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-2623-4094
Sylvie AmuDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
Ellen IacobaeusDepartment of Clinical Neuroscience, Division of Neurology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
Erik BobergDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0003-1304-0784
Katarina Le BlancDepartment of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Katarina.Leblanc@ki.se.
Karolinska University Hospital · SEKarolinska Institutet · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Graft versus host disease (GvHD) is the clinical condition in which bone marrow-derived mesenchymal stromal cells (MSCs) have been most frequently studied. In this review, we summarize the experience from clinical trials that have paved the way to translation. While MSC-based therapy has shown an exceptional safety profile, identifying potency assays and disease biomarkers that reliably predict the capacity of a specific MSC batch to alleviate GvHD has been difficult. As GvHD diagnosis and staging are based solely on clinical criteria, individual patients recruited in the same clinical trial may have vastly different underlying biology, obscuring trial outcomes and making it difficult to determine the benefit of MSCs in subgroups of patients. An accumulating body of evidence indicates the importance of considering not only the cell product but also patient-specific biomarkers and/or immune characteristics in determining MSC responsiveness. A mode of action where intravascular MSC destruction is followed by monocyte-efferocytosis-mediated skewing of the immune repertoire in a permissive inflammatory environment would both explain why cell engraftment is irrelevant for MSC efficacy and stress the importance of biologic differences between responding and nonresponding patients. We recommend a combined analysis of clinical outcomes and both biomarkers of disease activity and MSC potency assays to identify patients with GvHD who are likely to benefit from MSC therapy.

Indexed as

Graft vs Host DiseaseMesenchymal Stem CellsMesenchymal Stem Cell TransplantationHumansMonocytesacute GVHDchronic GVHDGVHDHematological malignanciesMSC

Identifiers

PMID37165014
PMCPMC10229573
OpenAlexW4376114166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.